NSUN2 promotes lung adenocarcinoma progression through stabilizing PIK3R2 mRNA in an m5C‐dependent manner

Abstract It is well known that 5‐methylcytosine (m 5 C) is involved in variety of crucial biological processes in cancers. However, its biological roles in lung adenocarcinoma (LAUD) remain to be determined. The LUAD samples were used to assess the clinical value of NOP2/Sun RNA Methyltransferase 2 (NSUN2). Dot blot was used to determine global m 5 C levels. ChIP and dual‐luciferase assays were performed to investigate the MYC‐associated zinc finger protein (MAZ)‐binding sites in NSUN2 promoter. RNA‐seq was used to explore the downstream molecular mechanisms of NSUN2. Dual luciferase reporter assay, m 5 C‐RIP‐qPCR, and mRNA stability assay were conducted to explore the effect of NSUN2‐depletion on target genes. Cell viability, transwell, and xenograft mouse model were designed to demonstrate the characteristic of NSUN2 in promoting LUAD progression. The m 5 C methyltransferase NSUN2 was highly expressed and caused elevated m 5 C methylation in LUAD samples. Mechanistically, MAZ positively regulated the transcription of NSUN2 and was related to poor survival of LUAD patients. Silencing NSUN2 decreased the global m 5 C levels, suppressed proliferation, migration and invasion, and inhibited activation of PI3K‐AKT signaling in A549 and SPAC‐1 cells. Phosphoinositide‐3‐Kinase Regulatory Subunit 2 (PIK3R2) was upregulated by NSUN2‐mediated m 5 C methylation by enhancing its mRNA stabilization and activated the phosphorylation of the PI3K‐AKT signaling. The present study explored the underlying mechanism and biological function of NSUN2‐meditated m 5 C RNA methylation in LUAD. NSUN2 was discovered to facilitate the malignancy progression of LUAD through regulating m 5 C modifications to stabilize PIK3R2 activating the PI3K‐AKT signaling, suggesting that NSUN2 could be a novel biomarker and promising therapeutic target for LUAD patients.